Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Lymphoma drug steps closer to approval

  • Comment
Zevalin ([90Y]-ibritumomab tiuxetan) has received a positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) as first line consolidation therapy for follicular lymphoma.

The CHMP’s recommendation for Zevalin, developed by Bayer Schering Pharma, will now be reviewed by the European Commission who will decide whether to grant marketing authorisation for all EU member states.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.